Literature DB >> 10543737

Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study.

C Thornsberry1, P T Ogilvie, H P Holley, D F Sahm.   

Abstract

An antimicrobial susceptibility surveillance study of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates was performed during the winter of 1996-1997 in order to determine their susceptibilities to 5 fluoroquinolones and 21 other antimicrobial agents. Broth microdilution MICs were determined for 2, 752 isolates from 51 U.S. medical centers. Of the 1,276 S. pneumoniae isolates, 64% were susceptible, 17% were intermediate, and 19% were highly resistant to penicillin. On the basis of the MICs at which 90% of isolates are inhibited and modal MICs, the hierarchy of the five fluoroquinolones from most to least active was grepafloxacin > sparfloxacin > levofloxacin = ciprofloxacin > ofloxacin. For S. pneumoniae isolates for which penicillin MICs were elevated, the MICs of the cephalosporins, macrolides, clindamycin, tetracycline, and trimethoprim-sulfamethoxazole were also elevated, but the MICs of the fluoroquinolones, vancomycin, and rifampin were not. The prevalence of penicillin-susceptible pneumococci varied by U.S. Bureau of the Census region (range, 44% in the East South Central region to 75% in the Pacific region). In addition, S. pneumoniae isolates from blood were significantly more susceptible to penicillin than those from respiratory, ear, or eye specimens, and pneumococci from patients </=2 years old were significantly more resistant to penicillin than those from older patients (by chi-square analysis, P < 0.05). beta-Lactamase was produced by 35% of H. influenzae isolates and 93% of M. catarrhalis isolates, resulting in increased MICs of amoxicillin and certain cephalosporins. We noted that the antimicrobial resistance patterns of S. pneumoniae isolates, which correlate with the penicillin susceptibility phenotype, vary by site of infection, age group of the patient, and geographic source of the isolate.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10543737      PMCID: PMC89533          DOI: 10.1128/AAC.43.11.2612

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program.

Authors:  G V Doern; M A Pfaller; K Kugler; J Freeman; R N Jones
Journal:  Clin Infect Dis       Date:  1998-10       Impact factor: 9.079

2.  Decrease in antibiotic susceptibility or increase in resistance?

Authors:  R D Walker; C Thornsberry
Journal:  J Antimicrob Chemother       Date:  1998-01       Impact factor: 5.790

3.  Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study.

Authors:  G V Doern; A B Brueggemann; G Pierce; T Hogan; H P Holley; A Rauch
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

4.  Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study.

Authors:  G V Doern; A Brueggemann; H P Holley; A M Rauch
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America.

Authors:  J G Bartlett; R F Breiman; L A Mandell; T M File
Journal:  Clin Infect Dis       Date:  1998-04       Impact factor: 9.079

6.  The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System.

Authors:  J C Butler; J Hofmann; M S Cetron; J A Elliott; R R Facklam; R F Breiman
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

7.  Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.

Authors:  C Thornsberry; P Ogilvie; J Kahn; Y Mauriz
Journal:  Diagn Microbiol Infect Dis       Date:  1997-12       Impact factor: 2.803

8.  Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study.

Authors:  G V Doern; A B Brueggemann; G Pierce; H P Holley; A Rauch
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

9.  Macrolide susceptibility and beta-lactamase production among haemophilus influenzae isolates in the United States, 1996-1997.

Authors:  P A Hogan; D J Sheehan
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

10.  Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system.

Authors:  J Sutcliffe; A Tait-Kamradt; L Wondrack
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

View more
  36 in total

1.  Identification of beta-lactamase-negative, ampicillin-resistant strains of Haemophilus influenzae with four methods and eight media.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999).

Authors:  R N Jones; M A Pfaller
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

3.  In vitro and In vivo activities of LB 10827, a new oral cephalosporin, against respiratory pathogens.

Authors:  K S Paek; M Y Kim; C S Lee; H Youn
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

4.  Levofloxacin-resistant Streptococcus pneumoniae: second look.

Authors:  C Thornsberry; J A Karlowsky; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

Review 5.  Role of beta-lactam agents in the treatment of community-acquired pneumonia.

Authors:  J Garau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

6.  Macrolide resistance in Streptococcus pneumoniae: Fallacy or fact?

Authors:  Jm Conly; Bl Johnston
Journal:  Can J Infect Dis       Date:  2002-01

7.  Surveillance of invasive Streptococcus pneumoniae infection in the province of Quebec, Canada, from 1996 to 1998: serotype distribution, Antimicrobial susceptibility, and clinical characteristics.

Authors:  L P Jetté; G Delage; L Ringuette; R Allard; P De Wals ; F Lamothe; V Loo
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

Review 8.  Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media.

Authors:  Jane Easton; Stuart Noble; Caroline M Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

Review 10.  New developments in antibacterial choice for lower respiratory tract infections in elderly patients.

Authors:  Anna Maria Ferrara; Anna Maria Fietta
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.